Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expands By 21.3%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 110,900 shares, a growth of 21.3% from the January 31st total of 91,400 shares. Based on an average daily trading volume, of 78,800 shares, the days-to-cover ratio is presently 1.4 days. Currently, 2.5% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Brainstorm Cell Therapeutics in a report on Sunday, March 2nd. They issued a “hold” rating for the company.

Brainstorm Cell Therapeutics Stock Performance

NASDAQ BCLI opened at $1.59 on Friday. The company has a market capitalization of $9.07 million, a PE ratio of -0.33 and a beta of 0.26. The business’s fifty day moving average is $1.94 and its 200 day moving average is $2.39. Brainstorm Cell Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $11.89.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.